Cytokinetics’ Myqorzo hits twin efficacy targets in genetic heart disease trial, while Viridian reports positive Phase 3 data for elegrobart

Cytokinetics announced that its experimental heart‑failure drug Myqorzo achieved both primary efficacy endpoints in a study of patients with genetic cardiomyopathy, showing significant symptom improvement.

The trial’s results were highlighted as meeting the study’s twin efficacy goals, suggesting the drug could address an unmet need in this patient population.

In related biotech news, Viridian Therapeutics disclosed positive top‑line results from a Phase 3 trial of elegrobart in chronic thyroid eye disease, indicating a favorable benefit‑risk profile.

Meanwhile, Vertex Pharmaceuticals reported first‑quarter earnings in line with expectations but said it is halting development of the mRNA cystic fibrosis candidate VX‑522 after tolerability concerns, and Pfizer and Alkermes also posted earnings.

Analysts are urged to scrutinize these developments closely, especially given ongoing discussions about other companies’ safety data.